Highly Commended, BMA Medical Book Awards 2014
Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.
Zusammenfassung
Highly Commended, BMA Medical Book Awards 2014Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.
Inhalt
An introduction to chronic myeloid leukemia. A historical perspective of chronic myeloid leukemia. Cytogenetics, molecular anatomy, and molecular biology of chronic myeloid leukemia. Clinical aspects, prognostic and predictive factors. Primary treatment of chronic myeloid leukemia. Secondary treatment and stem cell transplantation for chronic myeloid leukemia. Emerging and investigational treatment for chronic myeloid leukemia. Definitions of response and monitoring response for patients with chronic myeloid leukemia. Resistance to tyrosine kinase inhibitors and novel insights into genomic instability of chronic myeloid leukemia stem cells. Concluding thoughts.